Filing Flows › BioNexus Gene Lab (BGLC) › Q2 2026 › vs Q2 2025
BioNexus Gene Lab (BGLC) Q2 2026 vs Q2 2025 (year over year)
BioNexus Gene Lab's revenue fell $2.2M (-97%) from $2.3M in Q2 2025 to $76K in Q2 2026.
BioNexus Gene Lab, Q2 2026: revenue $76K (-97% year over year), operating margin -370.8%, net loss $286K, operating cash flow −$422K. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $76K | $2.3M | −$2.2M | -97% |
| Net loss | $286K | $616K | −$330K | -54% |
| Costs & expenses | $363K | $2.9M | −$2.5M | -87% |
| Operating costs | $359K | $2.9M | −$2.5M | -88% |
| Interest & other, net | $4K | $5K | −$1K | -17% |
| Cost of revenue | $63K | $1.9M | −$1.8M | -97% |
| Operating expenses | $295K | $979K | −$684K | -70% |
| Operating cash sources | $451K | $766K | −$315K | -41% |
| Depreciation | $28K | $28K | $265 | +1% |
| Cash used in operations | $422K | $738K | −$315K | -43% |
| Net loss absorbed | $286K | $616K | −$330K | -54% |
| Working capital & other | $164K | $150K | $15K | +10% |
Questions
How much did BioNexus Gene Lab's revenue grow year over year in Q2 2026?
BioNexus Gene Lab's revenue fell $2.2M (-97%) from $2.3M in Q2 2025 to $76K in Q2 2026.